ProCE Banner Activity

Conversaciones sobre el cáncer de mama RH positivo/HER2 negativo en el panorama terapéutico en expansión de los inhibidores de CDK4/6

PDF

Read these slide notes translated in Spanish to follow along with the associated downloadable slideset providing an overview of CDK4/6 inhibitors in HR+/HER2- breast cancer from early stage through metastatic disease.

Released: August 21, 2024

Expiration: August 20, 2025

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, Bydonis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, Dava Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru.

Primary Author

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Sara A. Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Celcuity, CytomX, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, Greenwich, Life Sciences, GlaxoSmithKline, Immunomedics, Lilly, Loxo, MacroGenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Puma, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks; individual publicly traded stock/stock options: ROM Tech.

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH: consultant/advisor/speaker: Arvinas, AstraZeneca, Lilly, Novartis.